These findings may be of clinical relevance should neurotransmitter pathways impacting tumor aggressiveness be actionable or reactivable in gliomas, whether it is through epigenetic-based strategies for IDH-mutated tumors or any other strategy for IDH-wt gliomas. This evidence concerns the gene IDH1 and neoplasm.